Jim Cramer Shared Insights on These 14 Stocks

11. Viking Therapeutics, Inc. (NASDAQ:VKTX)

Number of Hedge Fund Holders: 43

Viking Therapeutics, Inc. (NASDAQ:VKTX) is one of the stocks Jim Cramer shared insights on. When a caller asked about the company during the lightning round, Cramer commented:

“No, no, no. We have Eli Lilly. Why do we have to settle? Let’s, don’t, don’t go for the raggedy rest. Let’s go for the best.”

Viking Therapeutics, Inc. (NASDAQ:VKTX) is a clinical-stage biopharmaceutical company focused on therapies for metabolic and endocrine disorders. The company’s pipeline includes VK2809 for non-alcoholic steatohepatitis, along with candidates for diabetes, hip fracture recovery, obesity, and rare genetic conditions. When a caller asked about the stock in a January episode, Cramer responded:

“Okay, people, people think that even if Lily’s stock can’t go up, why would we want Viking Therapeutics? And a lot of people were in it for a takeover. So far it doesn’t look like that’s materializing, so they’re giving up and they are selling it. I prefer Eli Lilly.”

Since the above comment, Viking Therapeutics, Inc. (NASDAQ:VKTX) stock has declined by nearly 23%. The stock dropped over 40% between August 18 and 19 after the trial data of its oral anti-obesity drug showed that 20% of the patients dropped out due to negative effects.